Owkin Stock

owkin.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $279.77MM

Owkin is an AI biotech company using federated learning to connect biopharma companies and medical partners. Owkin's technology unlocks insights from siloed datasets that allow for the development of precise medical approaches to the treatment of disease. Owkin was founded in 2016 by Dr. Thomas Clozel and Dr. Gilles Wainrib and is headquartered in New York, NY.

Register To Buy and Sell Shares

For more details on financing and valuation for Owkin, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Owkin’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Owkin.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Hubert Chaperon
Chief Operating Officer
Darius Meadon
Chief Marketing Officer
Gilles Wainrib Ph.D
Co-Founder, Chief Scientific Officer & Board Member
Meriem Sefta Ph.D
Chief Diagnostics Officer & Chief Data and Clinical Solution Officer
Alban Sablière
Chief Business Officer
Jean-Philippe Vert
Chief Research and Development Officer
Jean-Frédéric Petit-Nivard
Chief Commercial Officer
Thomas Clozel MD
Co-Founder, Chief Executive Officer & Board Member
Mathieu Galtier Ph.D
Chief Data and Platform Officer
Vassili Soumelis
Chief Medical Officer
Andreas Emmenegger
Chief Financial Officer
Anna Huyghues-Despointes
Chief Corporate Development Officer
David Cahane
Chief Solutions Officer
Mariabrisa Olivares
Chief People Officer
Leo Cunningham
Chief Information Security Officer

Board Members

Jacky Abitbol
Cathay Innovation
Laurent Higueret, PharmD
Alex Pasteur
F-Prime Capital
Bruno Raillard
FRST Capital
Nicole Junkermann
NJF Holdings

Owkin’s stock FAQs


Can you buy Owkin’s stock?

Owkin is not publicly traded on NYSE or NASDAQ in the U.S. To buy Owkin’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Can you sell Owkin’s stock?

Yes, you can sell stock of a private company like Owkin. Forge can help you sell your Owkin stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.

What is Owkin’s stock price?

Owkin is a privately held company and therefore does not have a public stock price. However, you may access Owkin’s private market stock price with Forge Data.

What is Owkin’s stock ticker symbol?

Owkin does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Pigment, Payfit and Owkin-backer Frst has closed €72m of third fund

Paris-based VC firm Frst has closed €72m of its third fund, with investors including the European Investment Fund, Bpifrance, Axa Venture Partners, Isomer and Mubadala. The firm plans to invest the capital over four years into 30 seed-stage companies across various sectors, with investments ranging between €1m-3m. Frst aims to close the fund at €100m and is seeking more sovereign wealth funds, fund-of-funds and asset managers to invest.

Owkin invests $50M in spatial omics project that will 'revolutionize cancer research'

Owkin, an AI biotech company, has invested $50 million in a project using spatial omics to revolutionize cancer research. The project, named MOSAIC, will be conducted in collaboration with Nanostring Technologies and several leading cancer research institutions. Spatial omics allows researchers to examine tumors at near single-cell resolution, providing a detailed map of molecular interactions. The project aims to unlock the next wave of treatments for difficult-to-treat cancers.

MOSAIC Brings Big Guns to Spatial Genomics in Oncology

The Multi Omic Spatial Atlas in Cancer (MOSAIC) project, a collaboration involving several leading cancer research institutes, AI biotech pioneer Owkin, and spatial omics specialists NanoString, will mine 7,000 patient tumor samples for new biomarkers and therapeutics. Owkin is investing $50 million in the project, which aims to leverage spatial omics and AI to revolutionize oncology research and treatment.
Updated on: Jul 12, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.